The Archive · 6 posts
Innovating medical tech! 🚀 Creo Medical Group PLC (CREO) pioneers novel surgical endoscopy solutions on the London Stock Exchange. ⚡
Creo Medical grew H1 revenue by 45% to £3.2 million and cut its underlying operating loss by over 25% to £4.9 million.
July 28, 2026
Showing 5 of 6 posts
Creo Medical FY25: revenue up 50% to £6.0m, losses narrowing, but funding uncertainty remains with going concern warning.
JoshuaMay 22, 2026
Creo Medical delivers 60% Q1 revenue growth & targets 15% operating cost savings, setting a strong, efficient trajectory for FY26.
JoshuaApril 22, 2026
Creo Medical's FY25 results show a 50% revenue surge to £6m and a >40% cut in operating loss, marking major steps toward profitability.
JoshuaJanuary 20, 2026
Creo Medical's H1 shows 40% revenue surge & £20.5m cash. Strategic divestments & cost control fuel growth runway.
JoshuaJuly 21, 2025
Creo Medical's FY24: 74% core revenue surge, £8.7m cash boost & NHS validation. Strategic Micro-Tech partnership fuels growth in precision surgical tech.
JoshuaMay 19, 2025
January 20, 2026